Evidence map›Paper›PMID 35082823›Full record

ArticleDementia and geriatric cognitive disorders extra

Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease.

Yoshiyuki Kagawa, Yoshiaki Yamamoto, Ayami Ueno, Kengo Inomata, Mayu Tezuka, Takashi Osawa, Yasuharu Yazawa, Toshio Maeda, Tomokazu Obi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dementia and geriatric cognitive disorders extra. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yoshiyuki KagawaSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Yoshiaki YamamotoSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Ayami UenoSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Kengo InomataSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Mayu TezukaSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Takashi OsawaSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Yasuharu YazawaSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Toshio MaedaSchool of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics, University of Shizuoka, Shizuoka, Japan.
Tomokazu ObiDepartment of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
University of Shizuoka · JPNational Epilepsy Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe behavioral and psychological symptoms of dementia (BPSD) detract from the quality of life of not only dementia patients but also their family members and caregivers. Donepezil is used to treat Alzheimer's disease and is metabolized via cytochrome P450 (CYP) 2D6 and CYP3A4/5. It is controversial whether donepezil improves or exacerbates BPSD. This study investigated the relationships among BPSD, the pharmacokinetics of donepezil including its metabolite, 6-O-desmethyl donepezil, genetic polymorphisms of CYPs and P-glycoprotein, and patient backgrounds in 52 patients with Alzheimer's disease.

methodsBPSD were assessed using the Neuropsychiatric Inventory (NPI), with scores ≥20 points defined as severe BPSD. Plasma donepezil and 6-O-desmethyl donepezil concentrations were measured using liquid chromatography-tandem mass spectrometry.

resultsAlthough significant relationships between NPI scores and plasma donepezil concentrations were not seen, none of the 15 patients (29%) with high plasma donepezil concentrations (≥60 ng/mL) developed severe BPSD. Polymorphisms of DISCUSSION/

conclusionsThese results indicate that higher plasma concentrations of donepezil contribute to preventing or alleviating rather than developing or deteriorating BPSD.

Indexed as

Alzheimer's diseaseBehavioral and psychological symptoms of dementiaDonepezilPharmacokineticsPolymorphism

Identifiers

PMID35082823
PMCPMC8739384
OpenAlexW4200524763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.